Key insights
- Lucid Diagnostics (LUCD) priced an $18 million stock offering at $1.00 per share, anchored by a $15 million institutional investment. Proceeds will be used for working capital. This capital raise dilutes existing shareholders and signals potential short-term weakness for LUCD and possibly its parent company PAVmed (PAVM), with limited broader market implications.
Lucid Diagnostics Inc. (LUCD) announced the pricing of an underwritten registered direct offering of 18 million common shares at $1.00 per share. The medical diagnostics company said the offering was anchored by a $15 million investment from an institutional investor with support from an existing shareholder.
The gross proceeds from the offering are expected to be approximately $18 million before deducting underwriting discounts, commissions and other estimated offering expenses. Lucid plans to use the net proceeds for working capital and general corporate purposes.
The offering is expected to close on or about April 24, 2026, subject to customary closing conditions. Canaccord Genuity LLC and BTIG, LLC are serving as joint bookrunners for the offering.
The shares are being offered under a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on March 26, 2026.
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (PAVM). The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer.